Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MinCaRCT: Autologous minced cartilage vs matrix-associated autologous chondrocyte implantation for knee cartilage defects
2026-526179-49-00Phase 4Authorised
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Aug 2026
- Modality
- Cell Therapies, Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 4, randomised trial in cartilage defect of knee and Focal Knee Cartilage Defect comparing AMCI (Spherox) with MACI (2 arms). Primary endpoint: KOOS5 at 24 months. Planned start Aug 2026; status: authorised.
02
Drugs
autologous cultured chondrocytes on porcine collagen membraneCondrosphere
03
Conditions
cartilage defect of kneeFocal Knee Cartilage Defect
Beyond the preview
Go deeper on 2026-526179-49-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526179-49-00.